Join ASGT
|
Contact Us
|
Site Map
|
Home
Membership
Benefits of Membership
Types of Membership
Applying for Membership
Renew Your Membership
Member Directory
Update Contact Information
About the Society
Our Mission
History and Overview
Position Statements
Bylaws
Board, Officers and Advisory Council
Committee Members
ASGT Official Journal -
Molecular Therapy
Annual Meeting/Workshops
Future Annual Meetings
Archived Meetings Information
Archived Course Materials
Resources for Members
Member Directory
Job Bank
ASGT Grants/Awards
General Grant Information
Regulatory Affairs Information
• Federal Agencies that
Regulate Gene Therapy
• FDA References for the
Regulatory Process
• Clinical Trials and Regulatory
Affairs Information
• Regulatory Issues Archive
Related Sites of Interest
Welcome New Society Members!
Educational Resources
Learn About Gene Therapy
• What is Gene Therapy? Gene
Therapy Defined
• Common Gene Therapy Terms
• Gene Therapy for Diseases
• Gene Therapy vs. Cell Therapy
Gene Therapy in the News
• Breaking News
• ASGT News Releases
About Clinical Trials
Finding a Clinical Trial
Media Resources
• News Releases
• Guide to ASGT Gene Therapy
Experts
• ASGT Position Statements
2008 Annual Meeting
ASGT Special Plenary Session Evaluation
May 30, 2008
Special Plenary Session 320
1:30 pm – 3:30 pm
PRESENTATION RATINGS
Presenter/Topic
Overall Rating
Excellent
Good
Average
Poor
Very Poor
376. Ta-Chiang Liu, MD, PhD
- Clinical Proof-of-Concept with JX-594, a Novel Targeted Multi-Mechanistic Oncolytic Poxvirus, in Patients with Refractory Liver Tumors
377. Chiara Bonini, MD
- Transfer of a Suicide Gene into Donor Lymphocytes Allows Early and Effective Immune-Reconstitution after Family Haploidentical Hematopoietic Stem Cell Transplantation for Leukemias: Results of the TK007 Study
378. Toshifumi Yokota, PhD
- Body-Wide Restoration of Dystrophin Expression and Amelioration of Pathology in Dystrophic Dogs Using a Morpholino Cocktail
379. Defne Amado
- AAV-Mediated Delivery of Rod-Derived Cone Viability Factor: Towards a Mutation-Independent Prevention of Retinal Blindness
380. Yashuhiro Kazuki, PhD
- A Novel Human Artificial Chromosome (HAC) for Gene Therapy and Animal Transgenesis
381. Li Zhong, MD
- Next Generation of Recombinant Adeno-Associated Virus 2 Vectors: Point Mutations in Tyrosine Residues Lead to High-Efficiency Transduction at Lower Vector Doses
Comments
© 2000-2008 All rights reserved.
American Society of Gene Therapy
Disclaimer